Browse diseases

…s (SSc) is associated with significant morbidity and mortality. Pulmonary arterial hypertension (PAH) represents a negative prognostic factor, with a 3-year survival…

…tion Pulmonary arterial hypertension (PAH) develops in 6–12% of systemic sclerosis (SSc) and is a major cause of morbidity and mortality. Current guidel…

… Vasodilators, at least on monotherapy, should be considered in PVOD/PAH, as they seem to be well tolerated. Nevertheless, at follow…

… morbidity and mortality in a broad population of patients with pulmonary arterial hypertension (PAH), including those with PAH associated with systemic sclerosis (S…

…Introduction Risk stratification in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is crucial for optimizing treatment and improving outcomes. It …

…ulmonary hypertension occurred 2-4 years after the diagnosis of SSc-PAH. In cohort B, 11 patients died, of which one from cancer, three…

…DUs) are one of the most painful and disabling complications of systemic sclerosis (SSc). Nonetheless, good-quality interventional studies on SSc-DUs re…

…, mean age at diagnosis was 54+/-16 (table 1). The incidence of SSc was in average 3.85 per 100,000 person-years. The mean prevalen…

…ement is a frequent and clinically significant manifestation of systemic sclerosis (SSc), yet research has disproportionately focused on esophageal comp…